nach oben

Tumor Biology

Erschienen in:

01.06.2015 | Research Article

Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer

verfasst von: Chun-Hua Xu, Lan Cao, Xiu-Wei Zhang, Jun Yan, Li-Ke Yu

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

B7-H4, a member of the inhibitory B7 family, can restrain T cell proliferation, activation, and cytokine secretion and may be involved in immune evasion in cancer patients. This study aimed to evaluate the diagnostic and prognostic value of pleural effusion levels of soluble B7-H4 (sB7-H4) in lung cancer patients with malignant pleural effusion (MPE). Pleural effusion samples were collected from 98 lung cancer patients with malignant effusion and from 60 patients with nonmalignant pleural effusion. Pleural effusion concentrations of sB7-H4 were measured using sandwich enzyme-linked immunosorbent assay. Malignant effusion exhibited higher sB7-H4 levels than those in nonmalignant effusion (P < 0.01). Lung cancer patients with pleural effusion sB7-H4 levels below 35.8 ng/ml had a longer overall survival than those with higher levels (P < 0.05). By multivariate analysis, pleural effusion sB7-H4 was an independent prognostic factor in patients with MPE. In conclusion, measurement of sB7-H4 might be a useful diagnostic and prognostic value for MPE patients.

Kasahara K, Shibata K, Shintani H, Iwasa K, Sone T, et al. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer Res. 2006;26:1495–9.PubMed

Cheng D, Liang B, Li YH. Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Asian Pac J Cancer Prev. 2012;13:505–9.CrossRefPubMed

Xu CH, Zhan P, Yu LK, Zhang XW. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions. Tumour Biol. 2014;35:1599–603.CrossRefPubMed

Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, et al. Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest. 2004;125:987–9.CrossRefPubMed

Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology. 2008;13:5–20.CrossRefPubMed

Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757–63.CrossRefPubMed

Su WC, Lai WW, Chen HH, Hsiue TR, Chen CW, et al. Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study. Oncology. 2003;64:18–24.CrossRefPubMed

Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer. 2009;65:371–6.CrossRefPubMed

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.CrossRefPubMed

10.

Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006;66:1570–5.CrossRefPubMed

11.

Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.CrossRefPubMed

12.

Quandt D, Fiedler E, Boettcher D, Marsch WC, Seliger B. B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin Cancer Res. 2011;17:3100–11.CrossRefPubMed

13.

Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res. 2005;11:1842–8.CrossRefPubMed

14.

Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53:143–51.CrossRefPubMed

15.

Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100:44–52.CrossRefPubMed

16.

Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006;103:10391–6.CrossRefPubMedPubMedCentral

17.

Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104:19458–63.CrossRefPubMedPubMedCentral

18.

Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, et al. B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60:1047–55.CrossRefPubMed

19.

Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, et al. Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas. 2008;36:200–6.CrossRefPubMed

20.

Jiang J, Zhu Y, Wu C, Shen Y, Wei W, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010;59:1707–14.CrossRefPubMed

21.

Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst. 2010;102:26–38.CrossRefPubMedPubMedCentral

22.

Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfert RL, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer. 2008;99:1103–13.CrossRefPubMedPubMedCentral

23.

Simon I, Katsaros D, Rigault de la Longrai I, Massobrio M, Scorilas A, et al. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol. 2007;106:334–41.CrossRefPubMed

24.

Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2007;106:112–8.CrossRefPubMed

25.

Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008;68:6054–8.CrossRefPubMedPubMedCentral

26.

Arigami T, Uenosono Y, Hirata M, Hagihara T, Yanagita S, Ishigami S, et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol. 2010;102:748–52.CrossRefPubMed

27.

Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67:8900–5.CrossRefPubMed

Titel: Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer
verfasst von: Chun-Hua Xu
Lan Cao
Xiu-Wei Zhang
Jun Yan
Li-Ke Yu
Publikationsdatum: 01.06.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3079-x

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

DNA double-strand break repair gene XRCC7 genotypes were associated with hepatocellular carcinoma risk in Taiwanese males and alcohol drinkers

Stable knockdown of LRG1 by RNA interference inhibits growth and promotes apoptosis of glioblastoma cells in vitro and in vivo

MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition

New approaches for cancer immunotherapy

Adiponectin inhibits VEGF-A in prostate cancer cells

Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie